Skip to main content

Table 3 Cardiovascular benefits of SGLT2 inhibitors

From: Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

Agents

MACEs (HR)

CV death (HR)

HF (HR)

Renal outcome (HR)

Empagliflozin [56]

0.86

0.62

0.65

0.5

Canagliflozin [57]

0.86

0.87

0.67

0.6

Dapagliflozin [58]

0.93

0.98

0.73

0.76

Ertugliflozin [59]

0.97

0.92

0.7

0.81

Tofogliflozin [60]

–

–

–

–

Luseogliflozin [61]

–

–

–

–

Ipragliflozin [61]

–

–

–

–

  1. – limited data, MACE major adverse cardiac event, HR hazard ratio, CV cardiovascular, HF heart failure
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840